Quarterly ResultMay 15, 2026, 05:27 PM
Silexion Therapeutics Q1 Net Loss $2.73M; Cash $2.41M; Going Concern
AI Summary
Silexion Therapeutics Corp reported a net loss of $2.73 million for the first quarter of 2026, an increase from $1.74 million in the prior year. The company's cash and cash equivalents significantly decreased to $2.41 million as of March 31, 2026, from $5.99 million at the end of 2025. Management has concluded there is substantial doubt about the company's ability to continue as a going concern, as current funds are expected to last only several months. Operating expenses notably increased across R&D and G&A categories.
Key Highlights
- Net loss for Q1 2026 was $2.73 million, up from $1.74 million in Q1 2025.
- Cash and cash equivalents decreased to $2.41 million as of March 31, 2026, from $5.99 million on December 31, 2025.
- Management concluded substantial doubt exists about the company's ability to continue as a going concern.
- Total operating expenses increased to $2.75 million in Q1 2026 from $1.65 million in Q1 2025.
- Research and development expenses rose to $1.37 million in Q1 2026 from $0.59 million in Q1 2025.
- General and administrative expenses increased to $1.38 million in Q1 2026 from $1.06 million in Q1 2025.
- Net cash used in operating activities was $3.65 million in Q1 2026, compared to $2.45 million in Q1 2025.
- Shareholders' equity decreased to $291 thousand as of March 31, 2026, from $2.60 million on December 31, 2025.
Price Impact
More from SLXN